Amgen

Amgen is the new name of the Applied Molecular Genetics Company, and it is an American biopharmaceutical company. Amgen's headquarters are in Thousand Oaks, California. The company is best-known for two closely related drugs - Neulasta and Neupogen - which are used to prevent infections in patients who are undergoing chemotherapy. They are also the makers of Enbrel, Epogen, Aranesp, Sensipar/Mimpara, Nplate, Vectibix, Prolia, and XGEVA. As of 2016, there were over 19,000 people working for Amgen. Some of the employment opportunities at Amgen include sales positions, specialty representatives in a variety of fields including cardiovascular, tax reporting and finance workers, global health policy leads, clinical operations managers, and more.

The company was renamed Amgen (from Applied Molecular Genetics) in 1983, just a few years after incorporation and very likely to make the company more palatable during the initial public offering. The first chief executive officer was cofounder George Rathmann with Gordon Binder taking over in 1980. The current CEO is Robert Bradway. Since its beginning, Amgen has made more than five major acquisition, including medications that physicians and patients depend upon for various purposes. In 2016, Amgen purchased the rights to a T cell engager compound that is used to treat multiple myeloma.

Amgen does business all over the world in dozens of different countries. Some of the most notable ones include Australia, France, Germany, Canada, Ireland, Italy, the Netherlands, Poland, Romania, and Portugal. Amgen is a publicly traded company they reported revenues of $23.19 billion for the 2017 fiscal year. They also had revenue per share at $32.94. Amgen's quarterly revenue growth was at 4.3 percent while their quarterly earnings growth was at 6.7 percent.